---
document_datetime: 2025-12-25 11:05:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/aybintio.html
document_name: aybintio.html
version: success
processing_time: 0.1266224
conversion_datetime: 2025-12-26 09:28:01.150898
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Aybintio

[RSS](/en/individual-human-medicine.xml/67335)

##### Authorised

This medicine is authorised for use in the European Union

bevacizumab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Aybintio](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-81492)
- [More information](#more-information-911)
- [More information on Aybintio](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Aybintio is a cancer medicine that is used to treat adults with the following cancers:

- cancer of the colon (large bowel) or the rectum, when it has spread to other parts of the body;
- breast cancer that has spread to other parts of the body;
- a type of lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Aybintio can be used in non-small cell lung cancer unless it originates in cells of a particular type (called squamous cells);
- cancer of the kidney (renal cell carcinoma) that is advanced or has spread elsewhere;
- cancer of the ovary or associated structures (the fallopian tube that carries the egg from the ovary to the womb and the peritoneum, the membrane that lines the abdomen) that is advanced or has come back after treatment;
- cancer of the cervix (the neck of the womb) that has persisted or come back after treatment, or spread to other parts of the body.

Aybintio is used in combination with other cancer medicines, depending on the nature of any previous treatments or the presence of mutations (genetic changes) in the cancer that affect how well particular medicines work.

Aybintio is a 'biosimilar medicine'. This means that Aybintio is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Aybintio is Avastin. For more information on biosimilar medicines, see below.

Aybintio contains the active substance bevacizumab.

Expand section

Collapse section

## How is Aybintio used?

Aybintio can only be obtained with a prescription and treatment should be supervised by a doctor who has experience in the use of cancer medicines.

Aybintio is given by infusion (drip) into a vein. The first infusion of Aybintio should last 90 minutes, but subsequent infusions may be given more quickly if the first infusion has not caused unacceptable side effects. The dose depends on the patient's weight, the type of cancer being treated and the other cancer medicines being used. Treatment is continued for as long as the patient benefits from it. The doctor may decide to interrupt or stop treatment if the patient develops certain side effects.

For more information about using Aybintio, see the package leaflet or contact your doctor or pharmacist.

## How does Aybintio work?

The active substance in Aybintio, bevacizumab, is a monoclonal antibody (a type of protein) that has been designed to attach to vascular endothelial growth factor (VEGF), a protein that circulates in the blood and makes new blood vessels grow. By attaching to VEGF, Aybintio stops its effect. As a result, the cancer cannot develop its own blood supply and cancer cells are starved of oxygen and nutrients, helping to slow down the growth of tumours.

## What benefits of Aybintio have been shown in studies?

Laboratory studies comparing Aybintio with Avastin have shown that the active substance in Aybintio is highly similar to that in Avastin in terms of structure, purity and biological activity. Studies have also shown that giving Aybintio produces similar levels of the active substance in the body to giving Avastin.

In addition, a study involving 763 patients with advanced non-small cell lung cancer showed that Aybintio was as effective as Avastin when given with the cancer medicines paclitaxel and carboplatin. The cancer responded to treatment in 50% of those given Aybintio and 45% of those given Avastin, which was considered comparable.

Because Aybintio is a biosimilar medicine, the studies on effectiveness and safety of bevacizumab carried out with Avastin do not all need to be repeated for Aybintio.

## What are the risks associated with Aybintio?

The safety of Aybintio has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine Avastin.

The most common side effects with bevacizumab (which may affect more than 1 in 10 people) are hypertension (high blood pressure), tiredness or asthenia (weakness), diarrhoea and abdominal (belly) pain. The most serious side effects are gastrointestinal perforation (hole in the gut wall), haemorrhage (bleeding) and arterial thromboembolism (blood clots in the arteries). For the full list of all side effects reported with Aybintio, see the package leaflet.

Aybintio must not be used in people who are hypersensitive (allergic) to bevacizumab or any of the other ingredients, to Chinese hamster ovary cell products or other recombinant (genetically engineered) antibodies. It must not be given to pregnant women.

## Why is Aybintio authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Aybintio has a highly similar structure, purity and biological activity to Avastin and is distributed in the body in the same way. In addition, studies in non-small cell lung cancer have shown that the safety and effectiveness of Aybintio is equivalent to that of Avastin in this indication.

All these data were considered sufficient to conclude that Aybintio will behave in the same way as Avastin in terms of effectiveness and safety in its authorised uses. Therefore, the Agency's view was that, as for Avastin, the benefits of Aybintio outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Aybintio?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Aybintio have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Aybintio are continuously monitored. Side effects reported with Aybintio are carefully evaluated and any necessary action taken to protect patients.

## Other information about Aybintio

Aybintio received a marketing authorisation valid throughout the EU on 19 August 2020.

Aybintio : EPAR - Medicine overview

Reference Number: EMA/349890/2020

English (EN) (122.11 KB - PDF)

**First published:** 02/09/2020

[View](/en/documents/overview/aybintio-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-610)

български (BG) (172.08 KB - PDF)

**First published:**

02/09/2020

[View](/bg/documents/overview/aybintio-epar-medicine-overview_bg.pdf)

español (ES) (146.72 KB - PDF)

**First published:**

02/09/2020

[View](/es/documents/overview/aybintio-epar-medicine-overview_es.pdf)

čeština (CS) (170.5 KB - PDF)

**First published:**

02/09/2020

[View](/cs/documents/overview/aybintio-epar-medicine-overview_cs.pdf)

dansk (DA) (145.8 KB - PDF)

**First published:**

02/09/2020

[View](/da/documents/overview/aybintio-epar-medicine-overview_da.pdf)

Deutsch (DE) (150.03 KB - PDF)

**First published:**

02/09/2020

[View](/de/documents/overview/aybintio-epar-medicine-overview_de.pdf)

eesti keel (ET) (134.59 KB - PDF)

**First published:**

02/09/2020

[View](/et/documents/overview/aybintio-epar-medicine-overview_et.pdf)

ελληνικά (EL) (171.67 KB - PDF)

**First published:**

02/09/2020

[View](/el/documents/overview/aybintio-epar-medicine-overview_el.pdf)

français (FR) (148.19 KB - PDF)

**First published:**

02/09/2020

[View](/fr/documents/overview/aybintio-epar-medicine-overview_fr.pdf)

hrvatski (HR) (168.33 KB - PDF)

**First published:**

02/09/2020

[View](/hr/documents/overview/aybintio-epar-medicine-overview_hr.pdf)

italiano (IT) (145.33 KB - PDF)

**First published:**

02/09/2020

[View](/it/documents/overview/aybintio-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (177.79 KB - PDF)

**First published:**

02/09/2020

[View](/lv/documents/overview/aybintio-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (169.3 KB - PDF)

**First published:**

02/09/2020

[View](/lt/documents/overview/aybintio-epar-medicine-overview_lt.pdf)

magyar (HU) (168.79 KB - PDF)

**First published:**

02/09/2020

[View](/hu/documents/overview/aybintio-epar-medicine-overview_hu.pdf)

Malti (MT) (179.33 KB - PDF)

**First published:**

02/09/2020

[View](/mt/documents/overview/aybintio-epar-medicine-overview_mt.pdf)

Nederlands (NL) (146.81 KB - PDF)

**First published:**

02/09/2020

[View](/nl/documents/overview/aybintio-epar-medicine-overview_nl.pdf)

polski (PL) (172.63 KB - PDF)

**First published:**

02/09/2020

[View](/pl/documents/overview/aybintio-epar-medicine-overview_pl.pdf)

português (PT) (147.42 KB - PDF)

**First published:**

02/09/2020

[View](/pt/documents/overview/aybintio-epar-medicine-overview_pt.pdf)

română (RO) (168.42 KB - PDF)

**First published:**

02/09/2020

[View](/ro/documents/overview/aybintio-epar-medicine-overview_ro.pdf)

slovenčina (SK) (169.69 KB - PDF)

**First published:**

02/09/2020

[View](/sk/documents/overview/aybintio-epar-medicine-overview_sk.pdf)

slovenščina (SL) (166.23 KB - PDF)

**First published:**

02/09/2020

[View](/sl/documents/overview/aybintio-epar-medicine-overview_sl.pdf)

Suomi (FI) (144.23 KB - PDF)

**First published:**

02/09/2020

[View](/fi/documents/overview/aybintio-epar-medicine-overview_fi.pdf)

svenska (SV) (145.14 KB - PDF)

**First published:**

02/09/2020

[View](/sv/documents/overview/aybintio-epar-medicine-overview_sv.pdf)

Aybintio : EPAR - Risk-management-plan summary

English (EN) (31.53 KB - PDF)

**First published:** 02/09/2020

**Last updated:** 10/09/2021

[View](/en/documents/rmp-summary/aybintio-epar-risk-management-plan-summary_en.pdf)

## Product information

Aybintio : EPAR - Product information

English (EN) (1006.9 KB - PDF)

**First published:** 02/09/2020

**Last updated:** 22/12/2025

[View](/en/documents/product-information/aybintio-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-773)

български (BG) (768.19 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/bg/documents/product-information/aybintio-epar-product-information_bg.pdf)

español (ES) (599.37 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/es/documents/product-information/aybintio-epar-product-information_es.pdf)

čeština (CS) (774.21 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/cs/documents/product-information/aybintio-epar-product-information_cs.pdf)

dansk (DA) (784.89 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/da/documents/product-information/aybintio-epar-product-information_da.pdf)

Deutsch (DE) (625.51 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/de/documents/product-information/aybintio-epar-product-information_de.pdf)

eesti keel (ET) (625.06 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/et/documents/product-information/aybintio-epar-product-information_et.pdf)

ελληνικά (EL) (1.02 MB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/el/documents/product-information/aybintio-epar-product-information_el.pdf)

français (FR) (765.26 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/fr/documents/product-information/aybintio-epar-product-information_fr.pdf)

hrvatski (HR) (681.71 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/hr/documents/product-information/aybintio-epar-product-information_hr.pdf)

íslenska (IS) (620.86 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/is/documents/product-information/aybintio-epar-product-information_is.pdf)

italiano (IT) (788.44 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/it/documents/product-information/aybintio-epar-product-information_it.pdf)

latviešu valoda (LV) (765.22 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/lv/documents/product-information/aybintio-epar-product-information_lv.pdf)

lietuvių kalba (LT) (707.85 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/lt/documents/product-information/aybintio-epar-product-information_lt.pdf)

magyar (HU) (683.44 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/hu/documents/product-information/aybintio-epar-product-information_hu.pdf)

Malti (MT) (789.32 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/mt/documents/product-information/aybintio-epar-product-information_mt.pdf)

Nederlands (NL) (554.58 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/nl/documents/product-information/aybintio-epar-product-information_nl.pdf)

norsk (NO) (617.82 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/no/documents/product-information/aybintio-epar-product-information_no.pdf)

polski (PL) (728.87 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/pl/documents/product-information/aybintio-epar-product-information_pl.pdf)

português (PT) (640.7 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/pt/documents/product-information/aybintio-epar-product-information_pt.pdf)

română (RO) (677.94 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/ro/documents/product-information/aybintio-epar-product-information_ro.pdf)

slovenčina (SK) (606.65 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/sk/documents/product-information/aybintio-epar-product-information_sk.pdf)

slovenščina (SL) (718.42 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/sl/documents/product-information/aybintio-epar-product-information_sl.pdf)

Suomi (FI) (649.51 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/fi/documents/product-information/aybintio-epar-product-information_fi.pdf)

svenska (SV) (540.64 KB - PDF)

**First published:**

02/09/2020

**Last updated:**

22/12/2025

[View](/sv/documents/product-information/aybintio-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** 005106/R/0022 05/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Aybintio : EPAR - All authorised presentations

English (EN) (28.67 KB - PDF)

**First published:** 02/09/2020

[View](/en/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-303)

български (BG) (43.37 KB - PDF)

**First published:**

02/09/2020

[View](/bg/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_bg.pdf)

español (ES) (19.1 KB - PDF)

**First published:**

02/09/2020

[View](/es/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_es.pdf)

čeština (CS) (36.85 KB - PDF)

**First published:**

02/09/2020

[View](/cs/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.96 KB - PDF)

**First published:**

02/09/2020

[View](/da/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (19.05 KB - PDF)

**First published:**

02/09/2020

[View](/de/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (18.77 KB - PDF)

**First published:**

02/09/2020

[View](/et/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41.34 KB - PDF)

**First published:**

02/09/2020

[View](/el/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_el.pdf)

français (FR) (18.81 KB - PDF)

**First published:**

02/09/2020

[View](/fr/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (41.04 KB - PDF)

**First published:**

02/09/2020

[View](/hr/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (18.87 KB - PDF)

**First published:**

02/09/2020

[View](/is/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_is.pdf)

italiano (IT) (19.29 KB - PDF)

**First published:**

02/09/2020

[View](/it/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (41.1 KB - PDF)

**First published:**

02/09/2020

[View](/lv/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (36.2 KB - PDF)

**First published:**

02/09/2020

[View](/lt/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (26.83 KB - PDF)

**First published:**

02/09/2020

[View](/hu/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.17 KB - PDF)

**First published:**

02/09/2020

[View](/mt/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.98 KB - PDF)

**First published:**

02/09/2020

[View](/nl/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (19.06 KB - PDF)

**First published:**

02/09/2020

[View](/no/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_no.pdf)

polski (PL) (39.33 KB - PDF)

**First published:**

02/09/2020

[View](/pl/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_pl.pdf)

português (PT) (19.03 KB - PDF)

**First published:**

02/09/2020

[View](/pt/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_pt.pdf)

română (RO) (38.47 KB - PDF)

**First published:**

02/09/2020

[View](/ro/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (36.2 KB - PDF)

**First published:**

02/09/2020

[View](/sk/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (27.77 KB - PDF)

**First published:**

02/09/2020

[View](/sl/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (19.47 KB - PDF)

**First published:**

02/09/2020

[View](/fi/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (18.99 KB - PDF)

**First published:**

02/09/2020

[View](/sv/documents/all-authorised-presentations/aybintio-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Aybintio Active substance bevacizumab International non-proprietary name (INN) or common name bevacizumab Therapeutic area (MeSH)

- Colorectal Neoplasms
- Breast Neoplasms
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Uterine Cervical Neoplasms

Anatomical therapeutic chemical (ATC) code L01FG01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.

Aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1 of the SmPC.

Aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Aybintio in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1 of the SmPC.

Aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.

Aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1 of the SmPC).

Aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.

Aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1 of the SmPC).

Aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents.

Aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents (see section 5.1 of the SmPC).

Aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1 of the SmPC).

## Authorisation details

EMA product number EMEA/H/C/005106

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Samsung Bioepis NL B.V.

Olof Palmestraat 10 2616 LR Delft The Netherlands

Opinion adopted 25/06/2020 Marketing authorisation issued 19/08/2020 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Aybintio : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (131.48 KB - PDF)

**First published:** 21/07/2025

**Last updated:** 25/11/2025

[View](/en/documents/procedural-steps-after/aybintio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Aybintio : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (160.15 KB - PDF)

**First published:** 09/12/2020

**Last updated:** 02/12/2025

[View](/en/documents/procedural-steps-after/aybintio-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Aybintio-H-C-PSUSA-00000403-202202 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/921971/2022

English (EN) (125.12 KB - PDF)

**First published:** 15/12/2022

[View](/en/documents/scientific-conclusion/aybintio-h-c-psusa-00000403-202202-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Aybintio : EPAR - Public assessment report

Adopted

Reference Number: EMA/380645/2020

English (EN) (7.56 MB - PDF)

**First published:** 02/09/2020

[View](/en/documents/assessment-report/aybintio-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Aybintio

Adopted

Reference Number: EMA/CHMP/266464/2020

English (EN) (106.34 KB - PDF)

**First published:** 26/06/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-aybintio_en.pdf)

#### News on Aybintio

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2020) 26/06/2020

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Aybintio : EPAR - Product information - tracked changes

English (EN) (375.6 KB - DOCX)

**First published:** 03/12/2025

[View](/en/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-319)

български (BG) (306.2 KB - DOCX)

**First published:**

03/12/2025

[View](/bg/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_bg.docx)

español (ES) (258.5 KB - DOCX)

**First published:**

03/12/2025

[View](/es/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_es.docx)

čeština (CS) (273.46 KB - DOCX)

**First published:**

03/12/2025

[View](/cs/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (291.04 KB - DOCX)

**First published:**

03/12/2025

[View](/da/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (285.48 KB - DOCX)

**First published:**

03/12/2025

[View](/de/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (195.15 KB - DOCX)

**First published:**

03/12/2025

[View](/et/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (239.62 KB - DOCX)

**First published:**

03/12/2025

[View](/el/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_el.docx)

français (FR) (253 KB - DOCX)

**First published:**

03/12/2025

[View](/fr/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (215.63 KB - DOCX)

**First published:**

03/12/2025

[View](/hr/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (243.04 KB - DOCX)

**First published:**

03/12/2025

[View](/is/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_is.docx)

italiano (IT) (285.19 KB - DOCX)

**First published:**

03/12/2025

[View](/it/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (247.25 KB - DOCX)

**First published:**

03/12/2025

[View](/lv/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (201.63 KB - DOCX)

**First published:**

03/12/2025

[View](/lt/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (273.95 KB - DOCX)

**First published:**

03/12/2025

[View](/hu/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (267.28 KB - DOCX)

**First published:**

03/12/2025

[View](/mt/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (213.88 KB - DOCX)

**First published:**

03/12/2025

[View](/nl/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (228.47 KB - DOCX)

**First published:**

03/12/2025

[View](/no/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_no.docx)

polski (PL) (266.13 KB - DOCX)

**First published:**

03/12/2025

[View](/pl/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_pl.docx)

português (PT) (231.76 KB - DOCX)

**First published:**

03/12/2025

[View](/pt/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_pt.docx)

română (RO) (224.09 KB - DOCX)

**First published:**

03/12/2025

[View](/ro/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (193.88 KB - DOCX)

**First published:**

03/12/2025

[View](/sk/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (244.78 KB - DOCX)

**First published:**

03/12/2025

[View](/sl/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (216.31 KB - DOCX)

**First published:**

03/12/2025

[View](/fi/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (248.21 KB - DOCX)

**First published:**

03/12/2025

[View](/sv/documents/product-information-tracked-changes/aybintio-epar-product-information-tracked-changes_sv.docx)

#### More information

- [Biosimilar medicines: Overview](/en/human-regulatory-overview/biosimilar-medicines-overview)

#### More information on Aybintio

- [Real-life data study of the French cohort of patients with Rendu Osler disease treatment with bevacizumab:the CoBevaRO study. - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000548)

#### Topics

- [Biosimilars](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A45)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 22/12/2025

## Share this page

[Back to top](#main-content)